This randomized phase III trial compared pathologic complete response ( pCR ) rates of early breast cancer ( EBC ) following neoadjuvant epirubicin-docetaxel ( ED ) capecitabine ( C ) , and evaluated the addition of trastuzumab in HER2-positive tumors .